1. Home
  2. RFIL vs IKT Comparison

RFIL vs IKT Comparison

Compare RFIL & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$13.25

Market Cap

191.3M

Sector

Technology

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
IKT
Founded
1979
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.3M
220.5M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
RFIL
IKT
Price
$13.25
$2.41
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$11.25
$5.00
AVG Volume (30 Days)
231.7K
785.0K
Earning Date
06-15-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
57.76
EPS
0.07
N/A
Revenue
$55,325,000.00
N/A
Revenue This Year
$9.65
N/A
Revenue Next Year
$6.40
N/A
P/E Ratio
$187.86
N/A
Revenue Growth
10.22
N/A
52 Week Low
$5.54
$1.33
52 Week High
$22.30
$2.53

Technical Indicators

Market Signals
Indicator
RFIL
IKT
Relative Strength Index (RSI) 46.55 61.72
Support Level $13.10 $1.63
Resistance Level $13.50 $2.53
Average True Range (ATR) 0.83 0.13
MACD 0.28 -0.00
Stochastic Oscillator 82.62 70.89

Price Performance

Historical Comparison
RFIL
IKT

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: